Wall Street Zen Downgrades Biodexa Pharmaceuticals (NASDAQ:BDRX) to Sell

Biodexa Pharmaceuticals (NASDAQ:BDRX) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Monday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Biodexa Pharmaceuticals Price Performance

Shares of BDRX stock opened at $0.65 on Monday. The firm’s 50 day moving average price is $1.25 and its two-hundred day moving average price is $3.89. Biodexa Pharmaceuticals has a 52-week low of $0.65 and a 52-week high of $19.30.

Biodexa Pharmaceuticals shares are set to reverse split on Monday, April 6th. The 1-5 reverse split was announced on Wednesday, March 18th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, April 3rd.

Biodexa Pharmaceuticals (NASDAQ:BDRX) last announced its quarterly earnings data on Friday, March 27th. The company reported $0.70 EPS for the quarter. As a group, sell-side analysts expect that Biodexa Pharmaceuticals will post -1.25 earnings per share for the current fiscal year.

Institutional Trading of Biodexa Pharmaceuticals

A hedge fund recently bought a new stake in Biodexa Pharmaceuticals stock. Sabby Management LLC bought a new position in shares of Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 190,658 shares of the company’s stock, valued at approximately $433,000. Biodexa Pharmaceuticals makes up approximately 0.6% of Sabby Management LLC’s portfolio, making the stock its 10th largest position. Sabby Management LLC owned approximately 28.04% of Biodexa Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. 17.51% of the stock is currently owned by hedge funds and other institutional investors.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.